Petros Pharmaceuticals Valuation
| PTPIDelisted Stock | USD 0.03 0 13.35% |
Petros Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Petros Pharmaceuticals from analyzing the company fundamentals such as Shares Outstanding of 2.14 M, return on equity of -5.71, and Operating Margin of (2.41) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Petros Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Petros Pharmaceuticals is based on 3 months time horizon. Increasing Petros Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Petros Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Petros Pink Sheet. However, Petros Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0305 | Real 0.029 | Hype 0.0337 |
The intrinsic value of Petros Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Petros Pharmaceuticals' stock price.
Estimating the potential upside or downside of Petros Pharmaceuticals helps investors to forecast how Petros pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Petros Pharmaceuticals more accurately as focusing exclusively on Petros Pharmaceuticals' fundamentals will not take into account other important factors: Petros Pharmaceuticals Total Value Analysis
Petros Pharmaceuticals is at this time projected to have valuation of (1.42 M) with market capitalization of 265.45 K, debt of 7.39 M, and cash on hands of 13.3 M. The negative valuation of Petros Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Petros Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.42 M) | 265.45 K | 7.39 M | 13.3 M |
Petros Pharmaceuticals Investor Information
The company has price-to-book ratio of 0.45. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Petros Pharmaceuticals recorded a loss per share of 63.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 1st of May 2025. Based on the key indicators related to Petros Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Petros Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Petros Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Petros Pharmaceuticals has an asset utilization ratio of 48.07 percent. This signifies that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Petros Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Petros Pharmaceuticals Ownership Allocation
Petros Pharmaceuticals holds 7.39 pct. of its outstanding shares held by insiders and 6.79 pct. owned by third-party entities.Petros Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 5.11 M. Net Loss for the year was (14.32 M) with profit before overhead, payroll, taxes, and interest of 3.9 M.About Petros Pharmaceuticals Valuation
An absolute valuation paradigm, as applied to Petros Pink Sheet, attempts to find the value of Petros Pharmaceuticals based on its fundamental and basic technical indicators. By analyzing Petros Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Petros Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Petros Pharmaceuticals. We calculate exposure to Petros Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Petros Pharmaceuticals's related companies.Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on mens health therapeutics. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
8 Steps to conduct Petros Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Petros Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Petros Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Petros Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Petros Pharmaceuticals' revenue streams: Identify Petros Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Petros Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Petros Pharmaceuticals' growth potential: Evaluate Petros Pharmaceuticals' management, business model, and growth potential.
- Determine Petros Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Petros Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Petros Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 8 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Petros Pink Sheet
If you are still planning to invest in Petros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Petros Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |